Low-dose Imatinib Efficacy in a Gastrointestinal Stromal Tumor Patient With<i>KIT</i>Exon 11 W557_K558 Deletion
The response rate of GISTs to imatinib is influenced by genetic mutations. GIST with KIT exon 11 W557_K558 deletion is associated with a high risk of recurrence. In vitro data showed that low-dose imatinib was effective in such cases. Low-dose imatinib is a treatment option for patients with GIST harboring KIT exon 11 W557_K558 deletion who are intolerant to high-dose imatinib.
Authors
- Midori Morita (ORCID: https://orcid.org/0000-0003-4083-4432)
- Kazuyoshi Kajimoto
- Takuma Onoe
- Koji Matsumoto (ORCID: https://orcid.org/0000-0003-1907-0247)
- Hirotaka Suto
- Hideki Sakai
- Kyoko Ikeuchi
- Miyuki Kawamura
Institutions
- Hyogo Prefectural Cancer Center (JP)
Publication Details
- Journal
- In Vivo
- Published
- 2024-12-31
- DOI
- https://doi.org/10.21873/invivo.13857
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Nippon Shinyaku
- Eisai
- Daiichi Sankyo Europe